XNAS
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | 0.02 | -0.01 | -150.00% | $0 | ❌ Miss | -0.29% | -3.25% | — |
| 2026-03-19 | Q4 2025 | -0.01 | -0.01 | +0.00% | $0 | ➖ Inline | -0.48% | -6.04% | -6.68% |
| 2025-11-10 |
| Q3 2025 |
| -0.01 |
| -0.01 |
| +0.00% |
| $0 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.01 | -0.02 | -100.00% | $500,000 | ❌ Miss | +0.00% | -1.20% | +9.64% |
| 2025-03-26 | Q4 2024 | — | -0.01 | — | $0 | — | +1.69% | +0.00% | +5.49% |
| 2024-08-13 | Q2 2024 | — | -0.02 | — | $0 | — | +5.05% | +18.09% | +16.76% |
| 2024-05-15 | Q1 2024 | — | -0.01 | — | $0 | — | +3.15% | -5.68% | +34.07% |
| 2024-03-27 | FY 2023 | — | -0.04 | — | $10.0M | — | — | — | — |
Showing last 8 quarters.